drugset / Trial / NCT05125562
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
RandomizedParallel-groupTriple-blindTreatment
Summary
Early Mild Outpatient infusion Therapy with ExoFloTM for COVID-19 (EMOTE COVID-19) To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles, ExoFlo, as treatment for mild-moderate COVID-19.
Timeline
- Start
- 2022-12-07
- Primary completion
- 2023-03-07
- Completion
- 2023-03-07
Outcome
Outcome not reported
Stopped: “Sponsor has withdrawn/closed the IND with the FDA. A letter dated 21NOV2022 was submitted to the FDA.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ExoFlo | Other / unclassified | 10 ml | Intravenous |
| Subject | ExoFlo | Other / unclassified | 15 ml | Intravenous |